<p>B. Riley Wealth Advisors Inc. 在第二季度購買了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的新股份，根據其最近向證券交易委員會 (SEC) 提交的 13F 表格。該機構投資者購買了 4,141 股該製藥公司的股票，價值約為 1,844,000 美元。</p>
<ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下創造現金</li>
</ul>
<p>其他幾家大型投資者最近也增加或減少了對 VRTX 的持股。Activest Wealth Management 在第一季度獲得了價值約 25,000 美元的 Vertex Pharmaceuticals 新股份。Access Investment Management LLC 在第二季度購買了價值約 27,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Investment Solutions LLC 在第二季度獲得了價值約 29,000 美元的 Vertex Pharmaceuticals 新職位。Flaharty Asset Management LLC 在第一季度購買了價值 32,000 美元的 Vertex Pharmaceuticals 新職位。最後，American National Bank &amp; Trust 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 515.4%。American National Bank &amp; Trust 目前擁有 80 股該製藥公司的股票，價值 36,000 美元，此前在上個季度又購買了 67 股。90.96% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
<h2>Vertex Pharmaceuticals 股票上漲 1.4%</h2>
<p>VRTX 股票週一開盤價為 452.04 美元。該公司的 50 日移動平均線為 426.51 美元，200 日移動平均線為 425.47 美元。該公司的市值為 1,146.9 億美元，市盈率為 31.88，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 12 個月低點為 362.50 美元，12 個月高點為 519.68 美元。</p>
<ul>
<li>2025 年最佳生物技術股票</li>
</ul>
<p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近於 11 月 3 日發佈了季度財報。該製藥公司報告本季度每股收益為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。該季度的營業收入為 30.8 億美元，而一致預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。與去年同期相比，Vertex Pharmaceuticals 本季度的收入增長了 11.0%。在去年同期，該公司的每股收益為 4.38 美元。研究分析師平均預計 Vertex Pharmaceuticals Incorporated 本年度將發佈 15.63 的每股收益。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商最近對 VRTX 發佈了報告。Leerink Partners 在 9 月 25 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “持有” 上調至 “強力買入”。花旗集團在 10 月 2 日的報告中將 Vertex Pharmaceuticals 的目標價從 550.00 美元上調至 575.00 美元，並給予該股票 “買入” 評級。巴克萊在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 408.00 美元上調至 414.00 美元，並給予該公司 “等權重” 評級。加拿大皇家銀行在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 423.00 美元下調至 415.00 美元，並對該股票設定了 “行業表現” 評級。最後，Stifel Nicolaus 在 11 月 4 日的報告中將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並對該股票設定了 “持有” 評級。三位股票研究分析師對該股票給予了強力買入評級，十五位給予了買入評級，十位給予了持有評級。根據 MarketBeat.com 的數據，Vertex Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 498.42 美元。</p>
<ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
<p><strong>查看我們關於 Vertex Pharmaceuticals 的最新研究報告</strong></p>
<h2>Vertex Pharmaceuticals 的內部交易</h2>
<p>在 Vertex Pharmaceuticals 的其他新聞中，執行副總裁 Charles F. Wagner, Jr. 於 12 月 3 日出售了 14,000 股公司的股票，交易發生在該日。股票以平均價格 456.00 美元出售，總價值為 6,384,000.00 美元。出售完成後，該執行副總裁直接持有 37,725 股公司的股票，價值 17,202,600 美元。此次交易使其持股減少了 27.07%。該交易已在 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，董事長 Jeffrey M. Leiden 於 12 月 3 日在一筆交易中出售了 63,781 股公司的股票。股票以平均價格 449.20 美元出售，總交易額為 28,650,425.20 美元。交易完成後，董事長在公司持有 24,026 股，價值 10,792,479.20 美元。這代表其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。過去九十天內，內部人士共出售了價值 67,326,816 美元的 151,073 股公司股票。公司內部人士持有公司股票的 0.20%。</p>
<h2>關於 Vertex Pharmaceuticals</h2>
<p>(免費報告)</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化 (CF) 的療法。它為至少 2 歲或以上的 CF 患者提供 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者提供 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者提供 ORKAMBI；以及為 1 歲或以上的 CF 患者提供 ivacaftor 的 KALYDECO。</p>
<h2>特色故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>如何判斷一隻股票是否支付股息以及何時支付</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了實施階段</li>
<li>CD 計算器：定期存款計算器</li>
<li>在 10 年期國債利率上升時購買的 3 只金融股票</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
<p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場意識到之前購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
<p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

VERX

RILY

福泰制藥

<p>B. Riley Wealth Advisors Inc. 在第二季度收購了 4,141 股 Vertex Pharmaceuticals，價值約為 1,844,000 美元。此項收購已在他們向 SEC 提交的 13F 表格中報告。Vertex Pharmaceuticals 的股票表現良好，最近價格上漲，並且財報表現積極。幾位分析師給予了積極的評級，該公司的共識評級為 “適度買入”，目標價格為 498.42 美元</p>

<p>B. Riley Wealth Advisors Inc. bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,141 shares of the pharmaceutical company's stock, valued at approximately $1,844,000.</p>
<div class="lb-trans"><p>B. Riley Wealth Advisors Inc. 在第二季度購買了 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - 免費報告) 的新股份，根據其最近向證券交易委員會 (SEC) 提交的 13F 表格。該機構投資者購買了 4,141 股該製藥公司的股票，價值約為 1,844,000 美元。</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在沒有生物技術最大風險的情況下創造現金</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in VRTX. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals in the 1st quarter worth about $25,000. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the second quarter worth about $27,000. Legacy Investment Solutions LLC acquired a new position in Vertex Pharmaceuticals in the second quarter worth approximately $29,000. Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals in the first quarter valued at $32,000. Finally, American National Bank &amp; Trust lifted its position in shares of Vertex Pharmaceuticals by 515.4% during the 2nd quarter. American National Bank &amp; Trust now owns 80 shares of the pharmaceutical company's stock valued at $36,000 after acquiring an additional 67 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他幾家大型投資者最近也增加或減少了對 VRTX 的持股。Activest Wealth Management 在第一季度獲得了價值約 25,000 美元的 Vertex Pharmaceuticals 新股份。Access Investment Management LLC 在第二季度購買了價值約 27,000 美元的 Vertex Pharmaceuticals 新股份。Legacy Investment Solutions LLC 在第二季度獲得了價值約 29,000 美元的 Vertex Pharmaceuticals 新職位。Flaharty Asset Management LLC 在第一季度購買了價值 32,000 美元的 Vertex Pharmaceuticals 新職位。最後，American National Bank &amp; Trust 在第二季度將其在 Vertex Pharmaceuticals 的持股增加了 515.4%。American National Bank &amp; Trust 目前擁有 80 股該製藥公司的股票，價值 36,000 美元，此前在上個季度又購買了 67 股。90.96% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vertex Pharmaceuticals</strong> 警報：</p>
</div><h2>Vertex Pharmaceuticals Stock Up 1.4%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股票上漲 1.4%</h2>
</div><p>VRTX stock opened at $452.04 on Monday. The company has a 50 day moving average of $426.51 and a two-hundred day moving average of $425.47. The company has a market cap of $114.69 billion, a price-to-earnings ratio of 31.88 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68.</p>
<div class="lb-trans"><p>VRTX 股票週一開盤價為 452.04 美元。該公司的 50 日移動平均線為 426.51 美元，200 日移動平均線為 425.47 美元。該公司的市值為 1,146.9 億美元，市盈率為 31.88，貝塔值為 0.32。Vertex Pharmaceuticals Incorporated 的 12 個月低點為 362.50 美元，12 個月高點為 519.68 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技術股票</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, topping analysts' consensus estimates of $4.58 by $0.22. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. Vertex Pharmaceuticals's revenue for the quarter was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $4.38 earnings per share. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals (NASDAQ:VRTX - 獲取免費報告) 最近於 11 月 3 日發佈了季度財報。該製藥公司報告本季度每股收益為 4.80 美元，超出分析師一致預期的 4.58 美元，超出幅度為 0.22 美元。該季度的營業收入為 30.8 億美元，而一致預期為 30.5 億美元。Vertex Pharmaceuticals 的淨利潤率為 31.35%，股本回報率為 23.51%。與去年同期相比，Vertex Pharmaceuticals 本季度的收入增長了 11.0%。在去年同期，該公司的每股收益為 4.38 美元。研究分析師平均預計 Vertex Pharmaceuticals Incorporated 本年度將發佈 15.63 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages have recently issued reports on VRTX. Leerink Partnrs raised Vertex Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, September 25th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, October 2nd. Barclays upped their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the company an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Royal Bank Of Canada dropped their target price on shares of Vertex Pharmaceuticals from $423.00 to $415.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus cut their price target on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a report on Tuesday, November 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $498.42.</p>
<div class="lb-trans"><p>多家券商最近對 VRTX 發佈了報告。Leerink Partners 在 9 月 25 日的研究報告中將 Vertex Pharmaceuticals 的評級從 “持有” 上調至 “強力買入”。花旗集團在 10 月 2 日的報告中將 Vertex Pharmaceuticals 的目標價從 550.00 美元上調至 575.00 美元，並給予該股票 “買入” 評級。巴克萊在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 408.00 美元上調至 414.00 美元，並給予該公司 “等權重” 評級。加拿大皇家銀行在 11 月 4 日的研究報告中將 Vertex Pharmaceuticals 的目標價從 423.00 美元下調至 415.00 美元，並對該股票設定了 “行業表現” 評級。最後，Stifel Nicolaus 在 11 月 4 日的報告中將 Vertex Pharmaceuticals 的目標價從 455.00 美元下調至 445.00 美元，並對該股票設定了 “持有” 評級。三位股票研究分析師對該股票給予了強力買入評級，十五位給予了買入評級，十位給予了持有評級。根據 MarketBeat.com 的數據，Vertex Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 498.42 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：構建細胞和基因治療創新的未來</li>
</ul>
</div><p><strong>View Our Latest Research Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Vertex Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Insider Transactions at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的內部交易</h2>
</div><p>In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president directly owned 37,725 shares of the company's stock, valued at $17,202,600. The trade was a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the firm's stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the transaction, the chairman owned 24,026 shares in the company, valued at $10,792,479.20. This represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 151,073 shares of company stock valued at $67,326,816 over the last ninety days. Company insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在 Vertex Pharmaceuticals 的其他新聞中，執行副總裁 Charles F. Wagner, Jr. 於 12 月 3 日出售了 14,000 股公司的股票，交易發生在該日。股票以平均價格 456.00 美元出售，總價值為 6,384,000.00 美元。出售完成後，該執行副總裁直接持有 37,725 股公司的股票，價值 17,202,600 美元。此次交易使其持股減少了 27.07%。該交易已在 SEC 的法律文件中披露，相關信息可通過此鏈接獲取。此外，董事長 Jeffrey M. Leiden 於 12 月 3 日在一筆交易中出售了 63,781 股公司的股票。股票以平均價格 449.20 美元出售，總交易額為 28,650,425.20 美元。交易完成後，董事長在公司持有 24,026 股，價值 10,792,479.20 美元。這代表其持股減少了 72.64%。該銷售的 SEC 文件提供了更多信息。過去九十天內，內部人士共出售了價值 67,326,816 美元的 151,073 股公司股票。公司內部人士持有公司股票的 0.20%。</p>
</div><h2>About Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Vertex Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技術公司，專注於開發和商業化治療囊性纖維化 (CF) 的療法。它為至少 2 歲或以上的 CF 患者提供 TRIKAFTA/KAFTRIO；為 6 歲或以上的 CF 患者提供 SYMDEKO/SYMKEVI；為 1 歲或以上的 CF 患者提供 ORKAMBI；以及為 1 歲或以上的 CF 患者提供 ivacaftor 的 KALYDECO。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Vertex Pharmaceuticals</li>
<li>如何判斷一隻股票是否支付股息以及何時支付</li>
<li>Dave &amp; Buster’s 的反轉在雙底突破後進入了實施階段</li>
<li>CD 計算器：定期存款計算器</li>
<li>在 10 年期國債利率上升時購買的 3 只金融股票</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>迪士尼的 10 億美元交易將其魔力帶入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vertex Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vertex Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場意識到之前購買……而 Vertex Pharmaceuticals 並不在名單上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vertex Pharmaceuticals 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

B. Riley Wealth Advisors Inc. 購入了 4,141 股福泰製藥的股票